Ra Capital Management as of June 30, 2013
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 25 positions in its portfolio as reported in the June 2013 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals (ACAD) | 27.8 | $209M | 12M | 18.15 | |
| Achillion Pharmaceuticals | 10.3 | $77M | 9.5M | 8.18 | |
| Sangamo Biosciences (SGMO) | 8.7 | $65M | 8.4M | 7.81 | |
| Keryx Biopharmaceuticals | 6.6 | $50M | 6.7M | 7.47 | |
| Dyax | 5.0 | $38M | 11M | 3.46 | |
| Newlink Genetics Corporation | 4.8 | $36M | 1.8M | 19.72 | |
| Novavax | 4.7 | $35M | 17M | 2.05 | |
| Therapeuticsmd | 4.5 | $34M | 11M | 3.03 | |
| Insmed (INSM) | 3.9 | $29M | 2.4M | 11.96 | |
| Derma Sciences | 3.5 | $27M | 2.0M | 13.35 | |
| Sunesis Pharmaceuticals | 3.2 | $25M | 4.7M | 5.19 | |
| XOMA CORP Common equity shares | 3.2 | $24M | 6.7M | 3.63 | |
| Hyperion Therapeutics | 2.6 | $20M | 903k | 22.00 | |
| Receptos | 2.6 | $19M | 975k | 19.89 | |
| Omeros Corporation (OMER) | 2.0 | $15M | 3.0M | 5.04 | |
| OncoGenex Pharmaceuticals | 1.1 | $8.5M | 863k | 9.80 | |
| Enanta Pharmaceuticals (ENTA) | 1.0 | $7.7M | 436k | 17.71 | |
| Enzo Biochem (ENZ) | 0.9 | $7.0M | 3.3M | 2.08 | |
| Dynavax Technologies Corporation | 0.9 | $6.6M | 6.0M | 1.10 | |
| Prothena (PRTA) | 0.8 | $6.4M | 498k | 12.91 | |
| Arrowhead Research | 0.8 | $6.2M | 3.1M | 2.00 | |
| Epizyme | 0.6 | $4.2M | 151k | 28.13 | |
| Senomyx | 0.3 | $2.1M | 976k | 2.18 | |
| D Tranzyme | 0.2 | $1.3M | 2.7M | 0.47 | |
| Savient Pharmaceuticals note | 0.0 | $230k | 1.0M | 0.23 |
